| 1.08 -0.31 (-22.3%) | 10-07 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.78 |
1-year : | 2.21 |
| Resists | First : | 1.52 |
Second : | 1.89 |
| Pivot price | 1.39 |
|||
| Supports | First : | 0.93 |
Second : | 0.78 |
| MAs | MA(5) : | 1.35 |
MA(20) : | 1.42 |
| MA(100) : | 3.02 |
MA(250) : | 8.74 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2  |
| %K %D | K(14,3) : | 37.8 |
D(3) : | 49.3 |
| RSI | RSI(14): 26.1 |
|||
| 52-week | High : | 32.9 | Low : | 0.93 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NXTS ] has closed below the lower bollinger band by 31.8%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ NXTS ] is to continue within current trading range. It is unclear right now based on current values. 83.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 46 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.19 - 1.19 | 1.19 - 1.2 |
| Low: | 0.93 - 0.93 | 0.93 - 0.94 |
| Close: | 1.07 - 1.08 | 1.08 - 1.09 |
Nexentis Technologies Inc., through its subsidiary, develops therapeutics related to cancer and inflammatory metabolic diseases. It operates through two segments, Biotechnology Activity and Renewable Energy Projects. The company's pipeline includes MITOLINE, an algorithm used to perform multiple sequence/ structure pairwise alignments which could then be used for generating a 3D comparative model of potentially all mitochondrial carrier proteins; cloud-based computational chemistry platform; and novel in-vitro screening platforms; and advanced 3D NSCLC tumor spheroid systems.The company was formerly known as N2OFF, Inc. and changed its name to Nexentis Technologies Inc. in February 2026. Nexentis Technologies Inc. was incorporated in 2009 and is headquartered in Ness Ziona, Israel.
Wed, 07 Oct 2026
NXTS Stock Slides As Charts And Cash Flow Flash Caution - Timothy Sykes
Wed, 07 Oct 2026
NXTS Stock Compresses As Traders Study Key Levels - StocksToTrade
Wed, 07 Oct 2026
NXTS Stock Tests Volatility As Cash Cushion Buys Time - StocksToTrade
Wed, 07 Oct 2026
Google Cloud setup is expected to centralize scientific data management for drug researchers. - Stock Titan
Tue, 06 Oct 2026
Warrant amendments at Nexentis (NXTS) add no shares upon exercise and do not extend their terms. - Stock Titan
Mon, 05 Oct 2026
NXTS Forecast — Price Target — Prediction for 2027 - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Basic Materials
|
|
|
Industry:
Agricultural Inputs
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 21.1 (%) |
| Held by Institutions | 4.3 (%) |
| Shares Short | 63 (K) |
| Shares Short P.Month | 28 (K) |
| EPS | 8.15 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.3 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -29.6 % |
| Return on Equity (ttm) | -454.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.12 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -4 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | 0.13 |
| PEG Ratio | 0 |
| Price to Book value | 0.82 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.36 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|